FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002371645> ?p ?o ?g. }

• W2002371645 endingPage "e100" @default.
• W2002371645 startingPage "e99" @default.
• W2002371645 abstract "Editor, Despite the dramatic therapeutic effect of anti-Vascular Endothelial Growth Factor (VEGF) therapy for neovascular age-related macular degeneration (NV-AMD), concerns still linger regarding the potential for adverse events. Among its important physiological roles, VEGF maintains the microcirculation (Baffert et al. 2006; Papadopoulou et al. 2009) and protects neurons in the adaptive response to ischemic injury (Nishijima et al. 2007), which may be compromised by repeated intravitreal injection of anti-VEGF agents. Previous reports have documented suspected adverse systemic events including a sixth nerve palsy (Park & Guy 2007) and early loss of pregnancy following intravitreal injection of bevacizumab (Petrou et al. 2009). Here, we describe a patient who developed a microvascular third nerve palsy after multiple injections of bevacizumab and ranibizumab for NV-AMD. A 64 -year-old man with bilateral NV-AMD presented to the emergency room late at night with a marked reduction in adduction and elevation as well as ptosis of the right eye that were not initially documented earlier in the day by a general ophthalmologist or a family physician with whom the patient visited after waking up feeling dizzy and confused. In the ER, his pupils were reactive to light, there were no visual field cuts on confrontation test, optic disc margins were distinct, and there was no note of proptosis. CT angiogram revealed no evidence of any abnormalities of the major cerebral vessels, and a subsequent MRI scan showed no evidence of infarction and no abnormalities on the T2-weighted series. The patient’s past medical history includes 13 intravitreal bevacizumab injections in the right eye (last injection 16 days prior to incident) and seven injections of intravitreal bevacizumab followed by six ranibizumab injections in the left eye (last injection 14 days prior to incident). The patient’s medications also include candesartan for hypertension with which he takes faithfully (his blood pressure was measured to be 127/88 and 129/84 on two monthly visits for injection) and rabeprazole for gastroesophageal reflux. No other systemic conditions were reported. Follow-up evaluation 53 days later revealed a resolution of his double vision and ptosis with no abnormality of his eye movements. The clinical evidence points to an infarction of the third cranial nerve in the periphery because of a gradually developing occlusion of one of the small penetrating arteries on the surface of the nerve itself. As a vasodilator and endothelial survival factor, VEGF functions to maintain the tone and health of the microcirculation; intravitreal inhibition with ranibizumab has been reported to lead to significant arteriolar vasoconstriction from baseline 7 and 30 days after injection (Papadopoulou et al. 2009), and systemic VEGF inhibition in animal models leads to capillary regression and the disappearance of fenestrations over time (Baffert et al. 2006). VEGF also has a critical role as a neuroprotectant in the adaptive response to ischemic injury by directly promoting anti-apoptotic gene expression in neurons and upregulating blood flow via nitric oxide (Nishijima et al. 2007). However, both ranibizumab and bevacizumab can enter the systemic circulation; the latter may utilize endogenous immunoglobulin receptors to more effectively avoid degradation and circulate with a half life of approximately 10 days in humans (Cousins & Csaky 2009) while sustaining serum levels as high as 1 ug/ml 29 days post-injection in rabbits (Bakri et al. 2007). Since mean adult serum VEGF-A levels have been reported to be in the order of 100 pg/ml (Kimura et al. 2007), there could still be enough free bevacizumab in the human circulation after intravitreal injection to neutralize some VEGF actions. Consequently, physicians should remain cognizant of the potential relationship between microvascular disturbances and anti-VEGF therapy in an elderly AMD population. Funding/support: none; financial disclosures: none; other acknowledgements: none." @default.
• W2002371645 created "2016-06-24" @default.
• W2002371645 creator A5015086456 @default.
• W2002371645 creator A5024249255 @default.
• W2002371645 creator A5091511244 @default.
• W2002371645 date "2009-11-19" @default.
• W2002371645 modified "2023-09-26" @default.
• W2002371645 title "Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration" @default.
• W2002371645 cites W2024725915 @default.
• W2002371645 cites W2106557635 @default.
• W2002371645 cites W2141145436 @default.
• W2002371645 cites W2142693543 @default.
• W2002371645 cites W2163685069 @default.
• W2002371645 cites W2171085327 @default.
• W2002371645 doi "https://doi.org/10.1111/j.1755-3768.2009.01778.x" @default.
• W2002371645 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19925526" @default.
• W2002371645 hasPublicationYear "2009" @default.
• W2002371645 type Work @default.
• W2002371645 sameAs 2002371645 @default.
• W2002371645 citedByCount "4" @default.
• W2002371645 countsByYear W20023716452015 @default.
• W2002371645 countsByYear W20023716452016 @default.
• W2002371645 countsByYear W20023716452021 @default.
• W2002371645 crossrefType "journal-article" @default.
• W2002371645 hasAuthorship W2002371645A5015086456 @default.
• W2002371645 hasAuthorship W2002371645A5024249255 @default.
• W2002371645 hasAuthorship W2002371645A5091511244 @default.
• W2002371645 hasBestOaLocation W20023716451 @default.
• W2002371645 hasConcept C118487528 @default.
• W2002371645 hasConcept C126322002 @default.
• W2002371645 hasConcept C141071460 @default.
• W2002371645 hasConcept C197934379 @default.
• W2002371645 hasConcept C2776403814 @default.
• W2002371645 hasConcept C2776694085 @default.
• W2002371645 hasConcept C2777802072 @default.
• W2002371645 hasConcept C2781100027 @default.
• W2002371645 hasConcept C2781194658 @default.
• W2002371645 hasConcept C71924100 @default.
• W2002371645 hasConceptScore W2002371645C118487528 @default.
• W2002371645 hasConceptScore W2002371645C126322002 @default.
• W2002371645 hasConceptScore W2002371645C141071460 @default.
• W2002371645 hasConceptScore W2002371645C197934379 @default.
• W2002371645 hasConceptScore W2002371645C2776403814 @default.
• W2002371645 hasConceptScore W2002371645C2776694085 @default.
• W2002371645 hasConceptScore W2002371645C2777802072 @default.
• W2002371645 hasConceptScore W2002371645C2781100027 @default.
• W2002371645 hasConceptScore W2002371645C2781194658 @default.
• W2002371645 hasConceptScore W2002371645C71924100 @default.
• W2002371645 hasIssue "1" @default.
• W2002371645 hasLocation W20023716451 @default.
• W2002371645 hasLocation W20023716452 @default.
• W2002371645 hasOpenAccess W2002371645 @default.
• W2002371645 hasPrimaryLocation W20023716451 @default.
• W2002371645 hasRelatedWork W1995044506 @default.
• W2002371645 hasRelatedWork W2014975030 @default.
• W2002371645 hasRelatedWork W2034093159 @default.
• W2002371645 hasRelatedWork W2042956061 @default.
• W2002371645 hasRelatedWork W2123096760 @default.
• W2002371645 hasRelatedWork W2312597636 @default.
• W2002371645 hasRelatedWork W2336111296 @default.
• W2002371645 hasRelatedWork W2553987180 @default.
• W2002371645 hasRelatedWork W2559118752 @default.
• W2002371645 hasRelatedWork W4292631600 @default.
• W2002371645 hasVolume "89" @default.
• W2002371645 isParatext "false" @default.
• W2002371645 isRetracted "false" @default.
• W2002371645 magId "2002371645" @default.
• W2002371645 workType "article" @default.